Long-Term Protection from SARS-CoV-2 Variants in Mice by a Phase II Clinically Evaluated Original mRNA Vaccine Booster
The global coronavirus disease 2019 (COVID-19) pandemic was caused by SARS-CoV-2. The authors developed an mRNA vaccine (LVRNA009) that encoded the S protein of the Wuhan-Hu-1 strain and evaluated the long-term protection potential against SARS-CoV-2 variants. Mice were initially vaccinated with 2 d...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Compuscript Ltd
2024-04-01
|
| Series: | Zoonoses |
| Online Access: | https://www.scienceopen.com/hosted-document?doi=10.15212/ZOONOSES-2023-0060 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850284599552245760 |
|---|---|
| author | Jun Liu Jing Sun Liping Luo Yanhong Tang Hu Guo Yiyun He Qi Liu Xuya Yu Yumei Huang Siyuan Zhang Airu Zhu Jun Dai Fan Zhang Tao Huang Jincun Zhao Yucai Peng |
| author_facet | Jun Liu Jing Sun Liping Luo Yanhong Tang Hu Guo Yiyun He Qi Liu Xuya Yu Yumei Huang Siyuan Zhang Airu Zhu Jun Dai Fan Zhang Tao Huang Jincun Zhao Yucai Peng |
| author_sort | Jun Liu |
| collection | DOAJ |
| description | The global coronavirus disease 2019 (COVID-19) pandemic was caused by SARS-CoV-2. The authors developed an mRNA vaccine (LVRNA009) that encoded the S protein of the Wuhan-Hu-1 strain and evaluated the long-term protection potential against SARS-CoV-2 variants. Mice were initially vaccinated with 2 doses of LVRNA009, then boosted 8 months later. The virus neutralization titers against SARS-CoV-2 variants and antigen-specific T cell responses of the mice were determined. These animals were also tested using viral challenge experiments. Moreover, a phase II clinical study was carried out in 420 healthy adults. LVRNA009 vaccination induced neutralization antibodies and protected mice from SARS-CoV-2 original and Omicron BA.1.1 challenge 8 months post-boosting. A second booster dose of LVRNA009 further enhanced VNTs against Omicron variants. Clinical studies showed that LVRNA009 has good safety and immunogenicity profiles in humans. LVRNA009 could provide long-term protection against SARS-CoV-2 variants and confer better protection with a booster dose. These findings indicate that LVRNA009, a vaccine designed based on the original virus, might be effective in management of the COVID-19 pandemic. |
| format | Article |
| id | doaj-art-eff744b0e8b1449bbbfa83c0a8f6d035 |
| institution | OA Journals |
| issn | 2737-7466 2737-7474 |
| language | English |
| publishDate | 2024-04-01 |
| publisher | Compuscript Ltd |
| record_format | Article |
| series | Zoonoses |
| spelling | doaj-art-eff744b0e8b1449bbbfa83c0a8f6d0352025-08-20T01:47:32ZengCompuscript LtdZoonoses2737-74662737-74742024-04-014198210.15212/ZOONOSES-2023-0060Long-Term Protection from SARS-CoV-2 Variants in Mice by a Phase II Clinically Evaluated Original mRNA Vaccine BoosterJun LiuJing SunLiping LuoYanhong TangHu GuoYiyun HeQi LiuXuya YuYumei HuangSiyuan ZhangAiru ZhuJun DaiFan ZhangTao HuangJincun ZhaoYucai PengThe global coronavirus disease 2019 (COVID-19) pandemic was caused by SARS-CoV-2. The authors developed an mRNA vaccine (LVRNA009) that encoded the S protein of the Wuhan-Hu-1 strain and evaluated the long-term protection potential against SARS-CoV-2 variants. Mice were initially vaccinated with 2 doses of LVRNA009, then boosted 8 months later. The virus neutralization titers against SARS-CoV-2 variants and antigen-specific T cell responses of the mice were determined. These animals were also tested using viral challenge experiments. Moreover, a phase II clinical study was carried out in 420 healthy adults. LVRNA009 vaccination induced neutralization antibodies and protected mice from SARS-CoV-2 original and Omicron BA.1.1 challenge 8 months post-boosting. A second booster dose of LVRNA009 further enhanced VNTs against Omicron variants. Clinical studies showed that LVRNA009 has good safety and immunogenicity profiles in humans. LVRNA009 could provide long-term protection against SARS-CoV-2 variants and confer better protection with a booster dose. These findings indicate that LVRNA009, a vaccine designed based on the original virus, might be effective in management of the COVID-19 pandemic.https://www.scienceopen.com/hosted-document?doi=10.15212/ZOONOSES-2023-0060 |
| spellingShingle | Jun Liu Jing Sun Liping Luo Yanhong Tang Hu Guo Yiyun He Qi Liu Xuya Yu Yumei Huang Siyuan Zhang Airu Zhu Jun Dai Fan Zhang Tao Huang Jincun Zhao Yucai Peng Long-Term Protection from SARS-CoV-2 Variants in Mice by a Phase II Clinically Evaluated Original mRNA Vaccine Booster Zoonoses |
| title | Long-Term Protection from SARS-CoV-2 Variants in Mice by a Phase II Clinically Evaluated Original mRNA Vaccine Booster |
| title_full | Long-Term Protection from SARS-CoV-2 Variants in Mice by a Phase II Clinically Evaluated Original mRNA Vaccine Booster |
| title_fullStr | Long-Term Protection from SARS-CoV-2 Variants in Mice by a Phase II Clinically Evaluated Original mRNA Vaccine Booster |
| title_full_unstemmed | Long-Term Protection from SARS-CoV-2 Variants in Mice by a Phase II Clinically Evaluated Original mRNA Vaccine Booster |
| title_short | Long-Term Protection from SARS-CoV-2 Variants in Mice by a Phase II Clinically Evaluated Original mRNA Vaccine Booster |
| title_sort | long term protection from sars cov 2 variants in mice by a phase ii clinically evaluated original mrna vaccine booster |
| url | https://www.scienceopen.com/hosted-document?doi=10.15212/ZOONOSES-2023-0060 |
| work_keys_str_mv | AT junliu longtermprotectionfromsarscov2variantsinmicebyaphaseiiclinicallyevaluatedoriginalmrnavaccinebooster AT jingsun longtermprotectionfromsarscov2variantsinmicebyaphaseiiclinicallyevaluatedoriginalmrnavaccinebooster AT lipingluo longtermprotectionfromsarscov2variantsinmicebyaphaseiiclinicallyevaluatedoriginalmrnavaccinebooster AT yanhongtang longtermprotectionfromsarscov2variantsinmicebyaphaseiiclinicallyevaluatedoriginalmrnavaccinebooster AT huguo longtermprotectionfromsarscov2variantsinmicebyaphaseiiclinicallyevaluatedoriginalmrnavaccinebooster AT yiyunhe longtermprotectionfromsarscov2variantsinmicebyaphaseiiclinicallyevaluatedoriginalmrnavaccinebooster AT qiliu longtermprotectionfromsarscov2variantsinmicebyaphaseiiclinicallyevaluatedoriginalmrnavaccinebooster AT xuyayu longtermprotectionfromsarscov2variantsinmicebyaphaseiiclinicallyevaluatedoriginalmrnavaccinebooster AT yumeihuang longtermprotectionfromsarscov2variantsinmicebyaphaseiiclinicallyevaluatedoriginalmrnavaccinebooster AT siyuanzhang longtermprotectionfromsarscov2variantsinmicebyaphaseiiclinicallyevaluatedoriginalmrnavaccinebooster AT airuzhu longtermprotectionfromsarscov2variantsinmicebyaphaseiiclinicallyevaluatedoriginalmrnavaccinebooster AT jundai longtermprotectionfromsarscov2variantsinmicebyaphaseiiclinicallyevaluatedoriginalmrnavaccinebooster AT fanzhang longtermprotectionfromsarscov2variantsinmicebyaphaseiiclinicallyevaluatedoriginalmrnavaccinebooster AT taohuang longtermprotectionfromsarscov2variantsinmicebyaphaseiiclinicallyevaluatedoriginalmrnavaccinebooster AT jincunzhao longtermprotectionfromsarscov2variantsinmicebyaphaseiiclinicallyevaluatedoriginalmrnavaccinebooster AT yucaipeng longtermprotectionfromsarscov2variantsinmicebyaphaseiiclinicallyevaluatedoriginalmrnavaccinebooster |